Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

OABI vs CAMP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OABI Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 6–2 Matrix Metrics)

OABI Overall Winner 6-Pillar Tally: OABI 5 – 0 CAMP (1 Tie) Matrix Metrics: OABI 6 – 2 CAMP

As of Nov 17, 2026, OmniAb, Inc. (OABI) is the stronger overall head-to-head candidate over CAMP4 Therapeutics Corporation (CAMP) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OABI carries a Unified Composite Score of 56.2/100 (HOLD) at $5.00 (N/M Forward P/E, -92.9% operating margin), whereas CAMP carries 43.9/100 (HOLD) at $4.00 (N/M Forward P/E, -991.8% operating margin).

  • Growth vs. Quality Trade-Off: OABI earns the overall head-to-head edge with a stronger Unified Composite Score (56.2/100 HOLD vs. CAMP 43.9/100 HOLD) and 1.23β · 57% Vol risk profile, whereas CAMP leads top-line expansion (+138.9% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OABI vs CAMP
OABI NASDAQ Head-to-Head Winner
OmniAb, Inc. Common Stock
Services-Commercial Physical & Biological Research
$5.00
+2.25% 1D
Market Cap $716.2M
TTM Revenue $40M
Forward P/E N/M
Beta / 30D Vol 1.23β · 57% Vol
Unified Composite Score
56.2 / 100 HOLD
Tech 50.0 Fund 51.0 Flow 54.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.9% over 20 days), RSI 53
RSI-14: 52.6 · SMA20: $5.00 · SMA50: $4.77
CAMP NASDAQ
CAMP4 Therapeutics Corporation Common Stock
Pharmaceutical Preparations
$4.00
+3.63% 1D
Market Cap $238.5M
TTM Revenue $5.3M
Forward P/E N/M
Beta / 30D Vol 1.35β · 94% Vol
Unified Composite Score
43.9 / 100 HOLD
Tech 34.0 Fund 40.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.9 · SMA20: $3.82 · SMA50: $3.84

6-Pillar Scorecard Institutional Category Breakdown (OABI 5 – 0 CAMP)

Columns: Metric · OABI · CAMP
1. Valuation Multiples OABI
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 17.7x 26.6x
2. Growth & Scale OABI
Revenue Growth (YoY) +78.3% +138.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $40M $5.3M
Market Cap $716.2M $238.5M
3. Profitability & Quality OABI
Gross Margin 97.7% N/A
Operating Margin -92.9% -991.8%
Net Profit Margin -108.1% 0.0%
Return on Equity (ROE) -16.5% -146.1%
4. Balance Sheet & Cash Flow OABI
Cash Generation (TTM) $2.4M -$26M
Cash Flow Margin 5.9% N/A
Net Cash / Leverage $4.7M Net Cash $97M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OABI
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 83.3% (10th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OABI (6) vs CAMP (2)
Institutional Metric OABI CAMP Criterion Row Edge
Market Capitalization
Scale
$716.2M $238.5M Larger Scale OABI
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+78.3% +138.9% Higher Growth CAMP
Operating Margin (TTM)
Profitability
-92.9% -991.8% Higher Margin OABI
Net Profit Margin
Profitability
-108.1% 0.0% Higher Margin CAMP
Return on Equity (ROE)
Capital Efficiency
-16.5% -146.1% Higher ROE OABI
52-Week Range Position
Momentum
89% ($1–$5) 23% ($3–$8) Stronger Trend OABI
Beta / 30D Volatility
Risk Regime
1.23β · 57% Vol 1.35β · 94% Vol Lower Realized Risk OABI
Unified Institutional Score
Composite Signal
56.2 / 100 (HOLD) 43.9 / 100 (HOLD) Higher Composite OABI
Trailing 12M Revenue (USD)
Operating Scale
$40M $5.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
97.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 17.7x EV/Rev N/M PEG · 26.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.4M ($4.7M Net Cash) -$26M ($97M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAMP +20.78 pp
OABI: +6.61% · CAMP: +27.39%
3M Horizon OABI +33.31 pp
OABI: +19.33% · CAMP: -13.98%
6M Horizon OABI +114.58 pp
OABI: +110.97% · CAMP: -3.61%
1Y Horizon OABI +222.95 pp
OABI: +220.51% · CAMP: -2.44%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OABI Revenue CAMP Revenue OABI Op. Margin CAMP Op. Margin Margin Leader
FY2021 $30M N/A -102.5% N/A OABI
FY2022 $60M N/A -45.1% N/A OABI
FY2023 $30M $0M -203.2% -14822.6% OABI
FY2024 $30M $0M -282.3% -8142.3% OABI
FY2025 $20M $0M -369.5% -1502.4% OABI

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OABI SURGE
14d in phase · OBV NEUTRAL
Current IV 83.3%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact OABI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CAMP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CAMP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OABI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $716.2M market capitalization and -92.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CAMP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.5M market capitalization and -991.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OABI vs CAMP Key Questions & Quantitative Answers

As of Nov 17, 2026, OmniAb, Inc. (OABI) is the stronger overall head-to-head candidate over CAMP4 Therapeutics Corporation (CAMP) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OABI carries a Unified Composite Score of 56.2/100 (HOLD) at $5.00 (N/M Forward P/E, -92.9% operating margin), whereas CAMP carries 43.9/100 (HOLD) at $4.00 (N/M Forward P/E, -991.8% operating margin). Growth vs. Quality Trade-Off: OABI earns the overall head-to-head edge with a stronger Unified Composite Score (56.2/100 HOLD vs. CAMP 43.9/100 HOLD) and 1.23β · 57% Vol risk profile, whereas CAMP leads top-line expansion (+138.9% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.

OABI leads the Growth & Scale pillar: OABI posts +78.3% YoY revenue growth and +0.0% YoY earnings growth on $40M TTM revenue (97.7% gross margin, -92.9% operating margin), compared with CAMP at +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin). Across the 5-period historical trajectory (FY2021 to FY2025), OABI cumulative revenue shifted -33.3% while CAMP shifted N/A. In operating R&D and SG&A reinvestment, OABI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAMP.

OABI screens cheaper on headline valuation multiples. OABI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.7x EV/Revenue (5.9% FCF margin), whereas CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OABI (-16.5% ROE) versus CAMP (-146.1% ROE) capital efficiency.

In options market volatility and institutional positioning, OABI carries 83.3% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.23β · 57% Vol realized risk). By comparison, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.35β · 94% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.